Barbosa Ana Paula, Mascarenhas Mário Rui, Bicho Manuel, Janeiro João, Oliveira António Gouveia
University Clinic of Endocrinology, Lisbon University Medical School, Lisbon, Portugal.
Endocrinology, Diabetes and Metabolism Department, Santa Maria University Hospital, Lisbon, Portugal.
Osteoporos Sarcopenia. 2017 Sep;3(3):149-154. doi: 10.1016/j.afos.2017.08.099. Epub 2017 Sep 27.
The purpose of this study was to evaluate the effects of hyperthyroidism and their etiology on bone mineral density (BMD), on body soft tissue composition, on the prevalence of vertebral fractures detected by vertebral fracture assessment (VFA) and on the trabecular bone score (TBS).
From an initial population of 119 Portuguese men (78 with hyperthyroidism [HT]+ 41 controls [CTs]) admitted to the Endocrinology Department we selected 41 men aged over 50 with clinical hyperthyroidism to participate; each one was matched by age and height with a control person. BMD (g/cm) at the lumbar spine, hip, radius 33% and whole body and the total body masses (kg) were studied by dual-energy X-ray absorptiometry (DXA). VFA with Genant semiquantitative method was used to detect fractures. The TBS was obtained from lumbar spine DXA images. No patient had been treated previously for hyperthyroidism or osteoporosis. Adequate statistical tests were used.
In the hyperthyroidism group, total lean mass (CT 58.16 ± 7.7 vs. HT 52.3 ± 5.7, P = 0.03) and distal radius BMD (CT 0.769 ± 0.05 vs. HT 0.722 ± 0.08, P = 0.005) were lower; there was a significantly higher prevalence of osteoporosis (CT 9.7% vs. HT 29.3%, P = 0.015) and vertebral fractures (CT 2.4% vs. HT 24.4%, P = 0.007). TBS was similar in both groups (CT 1.328 ± 0.11 vs. HT 1.356 ± 0.11, P = not significant). Comparing patients with Graves' disease with patients with toxic goiter, there were no differences regarding BMD, BMD qualification, prevalence of fractures and TBS and just total lean mass was significantly lower in patients with Graves' disease.
These results suggest that in a group of hyperthyroid men aged over 50 there are significant decreases in cortical bone BMD and lean mass and a higher prevalence of osteoporosis and silent vertebral fractures, but the etiology of the hyperthyroidism does not seem to influence it. Besides the antithyroid drugs, some patients may benefit from bone-directed treatments.
本研究旨在评估甲状腺功能亢进及其病因对骨密度(BMD)、身体软组织成分、通过椎体骨折评估(VFA)检测到的椎体骨折患病率以及小梁骨评分(TBS)的影响。
从内分泌科收治的119名葡萄牙男性(78例甲状腺功能亢进症[HT]患者 + 41例对照者[CTs])的初始人群中,我们选取了41名年龄超过50岁的临床甲状腺功能亢进症男性参与研究;每例患者均按年龄和身高与一名对照者匹配。采用双能X线吸收法(DXA)研究腰椎、髋部、33%桡骨处及全身的骨密度(g/cm)和总体质量(kg)。采用Genant半定量方法的VFA检测骨折情况。TBS从腰椎DXA图像中获取。此前没有患者接受过甲状腺功能亢进症或骨质疏松症的治疗。使用了适当的统计学检验。
在甲状腺功能亢进症组中,总瘦体重(CT组58.16 ± 7.7 vs. HT组52.3 ± 5.7,P = 0.03)和桡骨远端骨密度(CT组0.769 ± 0.05 vs. HT组0.722 ± 0.08,P = 0.005)较低;骨质疏松症患病率(CT组9.7% vs. HT组29.3%,P = 0.015)和椎体骨折患病率(CT组2.4% vs. HT组24.4%,P = 0.007)显著更高。两组的TBS相似(CT组1.328 ± 0.11 vs. HT组1.356 ± 0.11,P = 无显著性差异)。比较格雷夫斯病患者和毒性甲状腺肿患者,在骨密度、骨密度分级、骨折患病率和TBS方面没有差异,仅格雷夫斯病患者的总瘦体重显著更低。
这些结果表明,在一组年龄超过50岁的甲状腺功能亢进症男性中,皮质骨骨密度和瘦体重显著降低,骨质疏松症和无症状椎体骨折的患病率更高,但甲状腺功能亢进症的病因似乎并未对其产生影响。除了抗甲状腺药物外,一些患者可能会从针对骨骼的治疗中获益。